GlaxoSmithKline Starts Phase 3 Severe Asthma Trial
March 18 2021 - 6:23AM
Dow Jones News
By Cecilia Butini
GlaxoSmithKline PLC said Thursday that it has kicked off a trial
as part of its Phase 3 clinical program to test a treatment for
severe eosinophilic asthma.
The trial, named SWIFT-2, is for an investigational medicine
called GSK'294, a monoclonal antibody which is meant to suppress
the protein responsible for the spread of eosinophils, a type of
white blood cell involved in severe asthma.
The medicine is delivered as a subcutaneous injection every six
months, GSK said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
March 18, 2021 06:08 ET (10:08 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Jun 2024 to Jul 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Jul 2023 to Jul 2024
